Research Analysts Issue Forecasts for XFOR FY2030 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at Brookline Capital Markets upped their FY2030 earnings per share estimates for X4 Pharmaceuticals in a note issued to investors on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $3.19 for the year, up from their prior forecast of $2.86. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.67) per share.

Separately, Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $3.24 on Monday. The business has a 50 day simple moving average of $3.20 and a 200 day simple moving average of $3.78. X4 Pharmaceuticals has a 52-week low of $2.43 and a 52-week high of $4.83. The company has a debt-to-equity ratio of 0.55, a current ratio of 13.22 and a quick ratio of 12.86.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. X4 Pharmaceuticals had a negative return on equity of 49.62% and a negative net margin of 474.74%. The business had revenue of $2.88 million during the quarter, compared to analyst estimates of $2.78 million.

Institutional Trading of X4 Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its position in shares of X4 Pharmaceuticals by 2,871.0% during the third quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock worth $618,000 after buying an additional 206,080 shares during the period. Alps Advisors Inc. grew its holdings in shares of X4 Pharmaceuticals by 36.2% during the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock worth $378,000 after buying an additional 34,698 shares in the last quarter. WINTON GROUP Ltd raised its position in X4 Pharmaceuticals by 35.8% in the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after buying an additional 3,800 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $313,000. Finally, AXQ Capital LP acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $107,000. 72.03% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO David Kirske sold 11,767 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at approximately $446,111.38. This represents a 7.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.13% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells. X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.